Esperante Ventures appeared to be the VC, which was created in 2004. The main department of described VC is located in the Hoofddorp. The company was established in Europe in The Netherlands.
Opposing the other organizations, this Esperante Ventures works on 8 percentage points less the average amount of lead investments. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2011. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 13 percentage points less often commits exit comparing to other organizations. The common things for fund are deals in the range of 1 - 5 millions dollars. The increased amount of exits for fund were in 2016.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the various public portfolio startups of the fund, we may underline Anergis, Atox Bio, Haemostatix
We also calculated 1 valuable employee in our database.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Esperante Ventures, startups are often financed by Spark Ventures, Northstar Ventures, Nesta Ventures. The meaningful sponsors for the fund in investment in the same round are Northstar Ventures, Longwall Venture Partners, Wellcome Trust. In the next rounds fund is usually obtained by Wellcome Trust, Sunstone Life Science Ventures, Renaissance PME Foundation.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Versantis | $17M | 18 Sep 2019 | Zürich, Zurich, Switzerland | ||
$2M | 03 Oct 2017 | England | |||
$588K | 14 Feb 2014 | England | |||
Cytox | $4M | 30 Jan 2013 | England | ||
$875K | 31 Aug 2012 | England | |||
Atox Bio | $3M | 19 Dec 2011 | North District | ||
Haemostatix | 01 Aug 2011 | Nottingham, England, United Kingdom | |||
Anergis | $20M | 28 Mar 2011 | Vaud, Switzerland | ||
Karus Therapeutics | $959K | 04 May 2010 | Test Valley, England, United Kingdom |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Versantis | $17M | 18 Sep 2019 | Zürich, Zurich, Switzerland | ||
$2M | 03 Oct 2017 | England | |||
$588K | 14 Feb 2014 | England | |||
Cytox | $4M | 30 Jan 2013 | England | ||
$875K | 31 Aug 2012 | England | |||
Atox Bio | $3M | 19 Dec 2011 | North District | ||
Haemostatix | 01 Aug 2011 | Nottingham, England, United Kingdom | |||
Anergis | $20M | 28 Mar 2011 | Vaud, Switzerland | ||
Karus Therapeutics | $959K | 04 May 2010 | Test Valley, England, United Kingdom |